Societal CDMO Inc (NAS:SCTL)

$ 1.1 0.01 (0.92%) Market Cap: 121.61 Mil Enterprise Value: 155.86 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 32/100

Q3 2023 Societal CDMO Inc Earnings Call Transcript
Nov 08, 2023

$0.3547 (+3.02%)

Earnings
Q2 2023 Societal CDMO Inc Earnings Call Transcript
Aug 14, 2023

$0.74 (-6.09%)

Earnings
Q1 2023 Societal CDMO Inc Earnings Call Transcript
May 10, 2023

$0.6901 (-1.41%)

Earnings
Q4 2022 Societal CDMO Inc Earnings Call Transcript
Mar 01, 2023

$1.44 (-2.04%)

Earnings
Q3 2022 Societal CDMO Inc Earnings Call Transcript
Nov 09, 2022

$1.54

Earnings
Q2 2022 Societal CDMO Inc Earnings Call Transcript
Aug 10, 2022

$1.07 (-4.46%)

Earnings
Q1 2022 Societal CDMO Inc Earnings Call Transcript
May 11, 2022

$1.23 (-1.60%)

Earnings
Q4 2021 Recro Pharma Inc Earnings Call Transcript
Mar 01, 2022

$1.68 (+1.20%)

Earnings
Q3 2021 Recro Pharma Inc Earnings Call Transcript
Nov 09, 2021

$1.88 (-1.05%)

Earnings
Recro Pharma Inc To Discuss Acquisition Of IriSys LLC Transcript
Aug 19, 2021
Q2 2021 Recro Pharma Inc Earnings Call Transcript
Aug 09, 2021

$1.96 (+3.70%)

Earnings
Q1 2021 Recro Pharma Inc Earnings Call Transcript
May 06, 2021

$2.51

Earnings
Recro Pharma Inc Annual Shareholders Meeting Transcript
Apr 20, 2021
Q4 2020 Recro Pharma Inc Earnings Call Transcript
Feb 26, 2021

$3.43 (-30.14%)

Earnings
Q3 2020 Recro Pharma Inc Earnings Call Transcript
Nov 09, 2020

$1.98 (+23.75%)

Earnings
Q2 2020 Recro Pharma Inc Earnings Call Transcript
Aug 10, 2020

$3.34 (-24.09%)

Earnings
Q1 2020 Recro Pharma Inc Earnings Call Transcript
May 11, 2020

$5.08 (-39.67%)

Earnings
Q4 2019 Recro Pharma Inc Earnings Call Transcript
Mar 04, 2020

$11 (-23.34%)

Earnings
Q3 2019 Recro Pharma Inc Earnings Call Transcript
Nov 08, 2019

$15.64 (+11.08%)

Earnings
Q2 2019 Recro Pharma Inc Earnings Call Transcript
Aug 08, 2019

$9.74 (+11.44%)

Earnings
Recro Pharma Inc at Jefferies Healthcare Conference Transcript
Jun 06, 2019
Q1 2019 Recro Pharma Inc Earnings Call Transcript
May 10, 2019

$8.16 (+3.42%)

Earnings
Recro Pharma Inc Corporate Update Call Transcript
Mar 22, 2019
Q4 2018 Recro Pharma Inc Earnings Call Transcript
Feb 19, 2019

Earnings

Q3 2020 Recro Pharma Inc Earnings Call Transcript

Nov 09, 2020 / 01:00PM GMT

Release Date Price: $1.98 (+23.75%)

Transcript 10-Q8-K

Operator

Good morning, and welcome to Recro's Third Quarter 2020 Financial Results Conference Call. (Operator Instructions)

I would now like to turn the conference call over to Claudia Styslinger with Investor Relations. You may begin.

Claudia Styslinger

Argot Partners, LLC - IR Associate

Good morning, and thank you for joining us on today's conference call to discuss Recro's third quarter 2020 financial results.

This is Claudia Styslinger, and I'm joined today by Gerri Henwood, President and Chief Executive Officer; and Ryan Lake, Chief Financial Officer. Following prepared remarks today by Gerri and Ryan, we will open the call for questions.

Earlier this morning, we issued a press release detailing our financial and operating results for the 3 and 9 months ended September 30, 2020. The press release is available on the Investors page of our website, at www.recrocdmo.com.

Before we begin our formal comments, I'll remind you that various remarks we make today

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.